On the basis of mutations detected in their organoids or in HNSCC in general, the same study also tested organoid sensitivity to several targeted therapies, including cetuximab, nutlin-3 (p53-MDM2 inhibitor), alpelisib (PIK3CA inhibitor), vemurafenib (BRAF inhibitor), everolimus (mTOR inhibitor), AZD4547 (FGFR inhibitor), and niraparib (PARP inhibitor) [31]. Here, BRAF is linked to head and neck squamous cell carcinoma.